Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gefarnate
- Development stage
- Phase 3
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Oral, Ophthalmic
01
Overview
Gefarnate is a terpene fatty acid ester, specifically geranyl farnesylacetate, that serves as a mucosal protective agent. It is primarily used in the treatment of gastric and duodenal ulcers and chronic erosive gastritis. Gefarnate enhances the defense mechanisms of the gastric mucosa by increasing prostaglandin levels and the concentration of amino hexoses, thereby promoting mucosal healing and protecting against injury induced by nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin. In addition to its gastrointestinal applications, gefarnate is utilized in ophthalmology to treat dry eye syndrome by stimulating goblet cell repopulation and mucin-like glycoprotein secretion on the ocular surface. Emerging research also indicates that gefarnate may possess lipid-lowering properties by activating the SIRT1-AMPK-mTOR pathway, which induces autophagy and accelerates the degradation of triglycerides in hepatocytes.
- Brand names
- GefarnilGefanil
- Other names
- geranyl farnesylacetategeranyl farnesyl acetategeranylfarnesyl acetategeraniol acetate
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)mTOR (Mammalian target of rapamycin kinase)MUC2 (Mucin-2)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on gefarnate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gefarnate.